{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:40:15Z","timestamp":1789584015768,"version":"build-2803163510"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00702-024-02825-8","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T16:02:20Z","timestamp":1726070540000},"page":"1471-1480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dopamine agonists in the treatment of Parkinson's disease: the show must go on"],"prefix":"10.1007","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3297","authenticated-orcid":false,"given":"Wolfgang H.","family":"Jost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"2825_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/mds.20200","volume":"19","author":"P Agarwal","year":"2004","unstructured":"Agarwal P, Fahn S, Frucht SJ (2004) Diagnosis and management of pergolide-induced fibrosis. Mov Disord 19:699\u2013704","journal-title":"Mov Disord"},{"key":"2825_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.2042-7158.1967.tb09604.x","volume":"19","author":"NE And\u00e9n","year":"1967","unstructured":"And\u00e9n NE, Rubenson A, Fuxe K et al (1967) Evidence for dopamine receptor stimulation by apomorphine. J Pharm Pharmacol 19:627\u2013629","journal-title":"J Pharm Pharmacol"},{"key":"2825_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","volume":"253","author":"P Barone","year":"2006","unstructured":"Barone P, Scarzella L, Marconi R et al (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson\u2019s disease: a national multicenter parallel group randomized study. J Neurol 253:601\u2013607","journal-title":"J Neurol"},{"key":"2825_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 9:573\u2013580","journal-title":"Lancet Neurol"},{"key":"2825_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1517\/14656566.3.2.197","volume":"3","author":"KM Biglan","year":"2002","unstructured":"Biglan KM, Holloway RG (2002) A review of pramipexole and its clinical utility in Parkinson\u2019s disease. Expert Opin Pharmacother 3:197\u2013210","journal-title":"Expert Opin Pharmacother"},{"key":"2825_CR14","doi-asserted-by":"crossref","unstructured":"Brecht HM (1998) Dopaminagonisten im Vergleich. In:Riederer P, Laux G, P\u00f6ldinger W. Neuro-Psychopharmaka. In: Band 5. Springer, Wien-New York, pp. 226\u2013240","DOI":"10.1007\/978-3-7091-6400-6_27"},{"key":"2825_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.20750","volume":"21","author":"A Castro-Caldas","year":"2006","unstructured":"Castro-Caldas A, Delwaide P, Jost W et al (2006) The Parkinson-CONTROL study: A 1-year, randomized, double-blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with Ldopa in Parkinson\u2019s disease. Mov Disord 21:500\u2013509","journal-title":"Mov Disord"},{"key":"2825_CR17","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1080\/03639045.2017.1349785","volume":"43","author":"B \u00c7elik","year":"2017","unstructured":"\u00c7elik B, \u00d6zdemir S, Barla Demirkoz A, \u00dcner M (2017) 2017 Optimization of piribedil mucoadhesive tablets for efficient therapy of Parkinson\u2019s disease: physical characterization and ex vivo drug permeation through buccal mucosa. Drug Dev Ind Pharm 43:1836\u20131845","journal-title":"Drug Dev Ind Pharm"},{"key":"2825_CR18","doi-asserted-by":"publisher","first-page":"1183823","DOI":"10.3389\/fneur.2023.1183823","volume":"14","author":"XT Chen","year":"2023","unstructured":"Chen XT, Zhang Q, Chen FF et al (2023) Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson\u2019s disease: a systematic review and network meta-analysis. Front Neurol 14:1183823","journal-title":"Front Neurol"},{"key":"2825_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/ene.12318","volume":"21","author":"M Chondrogiorgi","year":"2014","unstructured":"Chondrogiorgi M, Tatsioni A, Reichmann H, Konitsiotis S (2014) Dopamine agonist monotherapy in Parkinson\u2019s disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol 21:433\u2013440","journal-title":"Eur J Neurol"},{"key":"2825_CR20","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS et al (2014) The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain 137:2731\u20132742","journal-title":"Brain"},{"key":"2825_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2018.11.007","volume":"61","author":"M Contin","year":"2019","unstructured":"Contin M, Lopane G, Mohamed S et al (2019) Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 61:111\u2013117","journal-title":"Parkinsonism Relat Disord"},{"key":"2825_CR24","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S0140-6736(79)91725-2","volume":"1","author":"GU Corsini","year":"1979","unstructured":"Corsini GU, Del Zompo M, Gessa GL et al (1979) Therapeutic efficacy of apomorphin combined with an extracerebral inhibitor of dopamine receptors in Parkinson\u2019s disease. Lancet 1:954\u2013956","journal-title":"Lancet"},{"key":"2825_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.14740\/jocmr2541e","volume":"8","author":"R De Vecchis","year":"2016","unstructured":"De Vecchis R, Cantatrione C, Mazzei D et al (2016) Nonergot dopamine agonists do not increase the risk of heart failure in Parkinson\u2019s disease patients:Ameta-analysis of randomized controlled trials. J Clin Med Res 8:449\u2013460","journal-title":"J Clin Med Res"},{"key":"2825_CR28","first-page":"411","volume":"48","author":"WE De","year":"1884","unstructured":"De WE (1884) l\u2019apomorphine dans certain troubles nerveaux. Lyon Med 48:411\u2013419","journal-title":"Lyon Med"},{"key":"2825_CR29","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/mds.870130505","volume":"13","author":"RB Dewey","year":"1998","unstructured":"Dewey RB, Maraganore DM, Ahlskog JE et al (1998) A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson\u2019s disease. Mov Disord 13:782\u2013787","journal-title":"Mov Disord"},{"key":"2825_CR30","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"RB Dewey","year":"2001","unstructured":"Dewey RB, Hutton JT, LeWitt PA, Factor SA (2001) A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian offstate events. Arch Neurol 58:1385\u20131392","journal-title":"Arch Neurol"},{"key":"2825_CR32","first-page":"495","volume":"12","author":"M Dooley","year":"1998","unstructured":"Dooley M, Markham A (1998) Pramipexole. Drugs&aging 12:495\u2013514","journal-title":"Drugs&aging"},{"key":"2825_CR35","first-page":"124","volume":"5","author":"KM Eggert","year":"2012","unstructured":"Eggert KM, Oertel WH, Reichmann H et al (2012) Parkinson-syndrome: diagnostik und therapie. . In: Diener HC, Weimar C, et al. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie (5. Auflage). Leitlin F\u00fcr Diagn Ther der Neurol 5:124\u2013162","journal-title":"Leitlin F\u00fcr Diagn Ther der Neurol"},{"key":"2825_CR36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/WNF.0000000000000041","volume":"37","author":"K Eggert","year":"2014","unstructured":"Eggert K, \u00d6hlwein C, Kassubek J et al (2014) Influence of the non-ergot dopamine agonist piribedil on vigilance in patients with Parkinson disease and excessive daytime sleepiness (PiViCog-PD): An 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 37:116\u2013122","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl. 4","key":"2825_CR37","first-page":"S12","volume":"62","author":"SA Factor","year":"2004","unstructured":"Factor SA (2004) Intermittent subcutaneous apomorphine therapy in Parkinson\u2019s disease. Neurology 62(Suppl. 4):S12\u2013S17","journal-title":"Neurology"},{"key":"2825_CR38","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u20132508","journal-title":"N Engl J Med"},{"key":"2825_CR39","first-page":"19","volume":"61","author":"L Fei","year":"2019","unstructured":"Fei L, Zhou D, Ding ZT (2019) The efficacy and safety of rotigotine transdermal patch for the treatment of sleep disorders in Parkinson\u2019s disease: a meta-analysis. SleepMed 61:19\u201325","journal-title":"SleepMed"},{"key":"2825_CR40","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1017\/S1092852900013778","volume":"13","author":"JM Ferrara","year":"2008","unstructured":"Ferrara JM, Stacy M (2008) Impulse-control disorders in Parkinson\u2019s disease. CNS Spectr 13:690\u2013698","journal-title":"CNS Spectr"},{"key":"2825_CR41","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim S-Y et al (2018) International Parkinson and movement disorder society evidencebased medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 33:1248\u20131266","journal-title":"Mov Disord"},{"key":"2825_CR42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40263-019-00646-y","volume":"33","author":"JE Frampton","year":"2019","unstructured":"Frampton JE (2019) Rotigotine transdermal patch: a review in Parkinson\u2019s disease. CNS Drugs 33:707\u2013718","journal-title":"CNS Drugs"},{"key":"2825_CR44","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.21741","volume":"22","author":"N Giladi","year":"2007","unstructured":"Giladi N, Boroojerdi B, Korczyn AD et al (2007) Rotigotine transdermal patch in early Parkinson\u2019s disease: a ran- domized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398\u20132404","journal-title":"Mov Disord"},{"key":"2825_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/WNF.0b013e31821f0d8b","volume":"34","author":"A Gouraud","year":"2011","unstructured":"Gouraud A, Millaret A, Descotes J et al (2011) Piribedil induced sleep attacks in patients without Parkinson disease: a case series. Clin Neuropharmacol 34:104\u2013107","journal-title":"Clin Neuropharmacol"},{"key":"2825_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.wnf.0000162228.00154.ba","volume":"28","author":"WM G\u00fcldenpfennig","year":"2005","unstructured":"G\u00fcldenpfennig WM, Poole KH, Sommerville KW (2005) Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharamcol 28:106\u2013110","journal-title":"Clin Neuropharamcol"},{"key":"2825_CR48","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1365-2710.2012.01336.x","volume":"37","author":"N Hattori","year":"2012","unstructured":"Hattori N, Hasegawa K, Sakamoto T (2012) Pharmacokinetics and effect of food after oral administration of prolonged- release tablets of ropinirole hydrochloride in Japanese patients with Parkinson\u2019s disease. J Clin Pharm Ther 37:571\u2013577","journal-title":"J Clin Pharm Ther"},{"key":"2825_CR49","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/mds.21743","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Rascol O, Korczyn AD et al (2007) Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22:2409\u20132417","journal-title":"Mov Disord"},{"key":"2825_CR50","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1002\/mds.23317","volume":"25","author":"RA Hauser","year":"2010","unstructured":"Hauser RA, Schapira AHV, Rascol O et al (2010) Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson\u2019s disease. Mov Disord 25:2542\u20132549","journal-title":"Mov Disord"},{"key":"2825_CR51","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/mds.26697","volume":"31","author":"RA Hauser","year":"2016","unstructured":"Hauser RA, Olanow CW, Dzyngel B et al (2016) Sublingual apomorphine (APL-130277) for the acute conversion of OFF toONin Parkinson\u2019s disease. Mov Disord 31:1366\u20131372","journal-title":"Mov Disord"},{"key":"2825_CR54","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s00702-023-02686-7","volume":"130","author":"T Henriksen","year":"2023","unstructured":"Henriksen T, Katzenschlager R, Bhidayasiri R et al (2023) Practical use of apomorphine infusion in Parkinson\u2019s disease: lessons from the TOLEDO study and clinical experience. J Neural Transm 130:1475\u20131484","journal-title":"J Neural Transm"},{"key":"2825_CR55","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mds.23040","volume":"25","author":"BP Hersh","year":"2010","unstructured":"Hersh BP, Earl NL, Hauser RA, Stacy M (2010) Early treatment benefits of ropinirole prolonged release in Parkinson\u2019s patients with motor fluctuations. Mov Disord 25:927\u2013931","journal-title":"Mov Disord"},{"key":"2825_CR57","unstructured":"H\u00f6glinger G, Trenkwalder C et al. (2023) Parkinson-Krankheit, S2k-Leitlinie. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Online: (abgerufen am 12.02.2024)"},{"key":"2825_CR59","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/mds.20201","volume":"19","author":"J Horvath","year":"2004","unstructured":"Horvath J, Fross RD, Kleiner-Fisman G et al (2004) Severe multivalvular heart disease: a new complication of the ergot derivate dopamine agonists. Mov Disord 19:656\u2013662","journal-title":"Mov Disord"},{"key":"2825_CR60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/mds.870080208","volume":"6","author":"AJ Hughes","year":"1993","unstructured":"Hughes AJ, Bishop S, Kleedorfer B et al (1993) Subcutaneous apomorphine in Parkinson\u2019s disease: response to chronic administration for up to 5 years. Mov Disord 6:165\u2013170","journal-title":"Mov Disord"},{"key":"2825_CR61","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF00172952","volume":"95","author":"DM Jackson","year":"1988","unstructured":"Jackson DM, Jenkins OF, Ross SB (1988) The motor effects of bromocriptin \u2013 a review. Psychopharmacology Berl 95:433\u2013446","journal-title":"Psychopharmacology Berl"},{"issue":"S1","key":"2825_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0029-1245178","volume":"78","author":"WH Jost","year":"2010","unstructured":"Jost WH, Bergmann L (2010) Klinische Daten zur retardierten Formulierung von Ropinirol. Fortschr Neurol Psych 78(S1):20\u201324","journal-title":"Fortschr Neurol Psych"},{"key":"2825_CR63","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1055\/s-0038-1628823","volume":"29","author":"W Jost","year":"2010","unstructured":"Jost W, Eisenreich W (2010) Pramipexol Retard: Eine neue Therapieoption bei Morbus Parkinson. Nervenheilkunde 29:675\u2013681","journal-title":"Nervenheilkunde"},{"key":"2825_CR65","first-page":"102","volume":"15","author":"WH Jost","year":"2008","unstructured":"Jost WH, Kuhn K, Wangemann M (2008) Piribedil: ein neuer, bekannter Dopaminagonist. Psychopharmakotherapie 15:102\u2013109","journal-title":"Psychopharmakotherapie"},{"key":"2825_CR66","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1055\/s-0038-1628814","volume":"29","author":"W Jost","year":"2010","unstructured":"Jost W, Retzow A, Kuhn K (2010) Piribedil \u2013 ein non-ergot Dopaminagonist mit besonderem Rezeptorprofil. Ergebnisse von zwei Studien bei Patienten mit idiopathischem Parkinsonsyndrom im klinischen Alltag. Nervenheilkunde 29:571\u2013577","journal-title":"Nervenheilkunde"},{"key":"2825_CR67","doi-asserted-by":"crossref","unstructured":"Jost WH, Wang M, Wauer G, Dax A, Wedemeyer RS, Schug B, Warnke A, Leblanc A, Schurad B (2024) Skin adhesion of a newly developed, bioequivalent rotigotine patch formulation in comparison to the originator product: results of a multi-centre, randomised, crossover trial in patients with Parkinson\u2019s disease. Intern J Clin Pharmacol Ther; In press","DOI":"10.5414\/CP204672"},{"key":"2825_CR68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1741-7007-2-22","volume":"2","author":"JN Joyce","year":"2004","unstructured":"Joyce JN, Woolsey C, Ryoo H et al (2004) Lowdose pramipexole is neuroprotective in the MPTP mouse model of Parkinson\u2019s disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol 2:22","journal-title":"BMC Biol"},{"key":"2825_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-42","author":"J Kassubek","year":"2014","unstructured":"Kassubek J, Chaudhuri KR, Zesiewicz T et al (2014) Rotigotine transdermal system and evaluation of pain in patients with Parkinson\u2019s disease: a post hoc analysis of the RECOVER study. BMC Neurol. https:\/\/doi.org\/10.1186\/1471-2377-14-42","journal-title":"BMC Neurol"},{"key":"2825_CR70","doi-asserted-by":"publisher","unstructured":"Kassubek J, Jost WH, Schwarz J (2024) Sublingual apomorphine in the treatment of Parkinson\u2019s disease. J Neural Transm 131. https:\/\/doi.org\/10.1007\/s00702-024-02777-z.","DOI":"10.1007\/s00702-024-02777-z"},{"key":"2825_CR71","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","volume":"71","author":"R Katzenschlager","year":"2008","unstructured":"Katzenschlager R, Head J, Schrag A et al (2008) Fourteenyear final report of the randomized PDRG- UK trial comparing three initial treatments in PD. Neurology 71:474\u2013480","journal-title":"Neurology"},{"key":"2825_CR72","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebocontrolled trial. Lancet Neurol 17:749\u2013759","journal-title":"Lancet Neurol"},{"key":"2825_CR73","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/mds.870130112","volume":"13","author":"AD Korczyn","year":"1998","unstructured":"Korczyn AD, Brooks D, Brunt ER et al (1998) Ropinirol versus bromocriptine in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 3-year study. Mov Disord 13:46\u201351","journal-title":"Mov Disord"},{"key":"2825_CR74","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00702-006-0606-3","volume":"114","author":"AD Korczyn","year":"2007","unstructured":"Korczyn AD, Reichmann H, Boroojerdi B, H\u00e4ck HJ (2007) Rotigotine transdermal system for perioperative administration. J Neural Transm 114:219\u2013221","journal-title":"J Neural Transm"},{"key":"2825_CR76","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","volume":"28","author":"T Kvernmo","year":"2006","unstructured":"Kvernmo T, H\u00e4rtter S, B\u00fcrger E (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Therapeut 28:1065\u20131078","journal-title":"Clin Therapeut"},{"key":"2825_CR77","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1185\/030079902125000741","volume":"18","author":"C Lebrun-Frenay","year":"2002","unstructured":"Lebrun-Frenay C, Borg M (2002) Choosing the right dopamine agonist for patients with Parkinson\u2019s disease. Curr Med Res Opin 18:209\u2013214","journal-title":"Curr Med Res Opin"},{"key":"2825_CR79","first-page":"1262","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system. PREFER Study Neurology 68:1262\u20131267","journal-title":"PREFER Study Neurology"},{"key":"2825_CR80","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00702-012-0925-5","volume":"120","author":"PA Lewitt","year":"2013","unstructured":"LeWitt PA, Boroojerdi B, Surmann E, Poewe W (2013) Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson\u2019s disease: results of two open-label extension studies CLEOPATRA-PD and PREFER. J Neural Transm 120:1069\u20131081","journal-title":"J Neural Transm"},{"key":"2825_CR81","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000486252","volume":"45","author":"BD Li","year":"2018","unstructured":"Li BD, Cui JJ, Song J et al (2018) Comparison of the efficacy of different drugs on non-motor symptoms of Parkinson\u2019s disease: a network meta-analysis. Cell Physiol Biochem 45:119\u2013130","journal-title":"Cell Physiol Biochem"},{"key":"2825_CR82","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/WNL.49.1.162","volume":"49","author":"A Lieberman","year":"1997","unstructured":"Lieberman A, Ranhosky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson\u2019s disease: results of a double-blind, placebo-controlled, parallelgroup study. Neurology 49:162\u2013168","journal-title":"Neurology"},{"key":"2825_CR83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/brain\/124.2.331","volume":"124","author":"AJ Manson","year":"2001","unstructured":"Manson AJ, Hanagasi H, Turner K et al (2001) Intravenous apomorphine therapy in Parkinson\u2019s disease. Brain 124:331\u2013340","journal-title":"Brain"},{"key":"2825_CR84","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1098\/rspl.1868.0094","volume":"17","author":"A Matthiesen","year":"1869","unstructured":"Matthiesen A, Wright CRA (1869) Researches into the chemical constitution of the opium bases, part 1. on the action of hydrochloric acid on morphia. Proc R Soc London 17:455\u2013460","journal-title":"Proc R Soc London"},{"issue":"26","key":"2825_CR85","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.2174\/1381612826666200316154300","volume":"2020","author":"S Md","year":"2020","unstructured":"Md S, Karim S, Aldawsari HM (2020) Current status and challenges in rotigotine delivery. Curr Pharm Des 2020(26):2222\u20132232","journal-title":"Curr Pharm Des"},{"key":"2825_CR87","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s001150170004","volume":"72","author":"W Meissner","year":"2001","unstructured":"Meissner W, Trottenberg T, Klaffke S et al (2001) Apomorphintherapie versus tiefe Hirnstimulation. Nervenarzt 72:924\u2013927","journal-title":"Nervenarzt"},{"key":"2825_CR89","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00002826-200105000-00008","volume":"24","author":"LV Metmann","year":"2001","unstructured":"Metmann LV, Gillespie M, Farmer C et al (2001) Continuous transdermal dopaminergic stimulation in advanced Parkinson\u2019s disease. Clin Neuropharmacol 24:163\u2013169","journal-title":"Clin Neuropharmacol"},{"key":"2825_CR90","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.parkreldis.2014.10.005","volume":"20","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Nomoto M, Haesgawa K et al (2014) Rotigotine vs ropinirole in advanced stage Parkinson\u2019s disease: a double-blind study. Parkinsonism Rel Disord 20:1388\u20131393","journal-title":"Parkinsonism Rel Disord"},{"key":"2825_CR91","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/mds.20397","volume":"20","author":"JC M\u00f6ller","year":"2005","unstructured":"M\u00f6ller JC, Oertel WH, K\u00f6ster J et al (2005) Long-term efficacy and safety of pramipexole in advanced Parkinson\u2019s disease: results from a European multicenter trial. Mov Disord 20:602\u2013610","journal-title":"Mov Disord"},{"key":"2825_CR92","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/1531-8257(199903)14:2<336::AID-MDS1021>3.0.CO;2-9","volume":"14","author":"JL Montastruc","year":"1999","unstructured":"Montastruc JL, Ziegler M, Rascol O, Malbezin M (1999) A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson\u2019s disease. Mov Disord 14:336\u2013341","journal-title":"Mov Disord"},{"key":"2825_CR96","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1474-4422(19)30396-5","volume":"19","author":"CW Olanow","year":"2020","unstructured":"Olanow CW, Factor SA, Espay AJ et al (2020a) Apomorphine sublingual film for off episodes in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol 19:135\u2013144","journal-title":"Lancet Neurol"},{"key":"2825_CR97","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/mds.28027","volume":"35","author":"CW Olanow","year":"2020","unstructured":"Olanow CW, Standaert DG, Kieburtz K, Viegas TX, Moreadith R (2020b) Once-weekly subcutaneous delivery of polymer- linked rotigotine (SER-214) provides continuous plasma levels in Parkinson\u2019s disease patients. Mov Disord 35:1055\u20131061","journal-title":"Mov Disord"},{"key":"2825_CR98","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Stacy MA, Factor SA et al (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68:1108\u20131115","journal-title":"Neurology"},{"key":"2825_CR99","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 284:1931\u20131938","journal-title":"JAMA"},{"key":"2825_CR100","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653\u20131661","journal-title":"JAMA"},{"key":"2825_CR101","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","volume":"60","author":"Parkinson Study Group","year":"2003","unstructured":"Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson\u2019s disease. Arch Neurol 60:1721\u20131728","journal-title":"Arch Neurol"},{"issue":"Suppl 3","key":"2825_CR102","first-page":"A81","volume":"58","author":"RG Holloway","year":"2002","unstructured":"Parkinson Study Group, Holloway RG (2002) Pramipexole versus levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Neurology 58(Suppl 3):A81\u2013A82","journal-title":"Neurology"},{"key":"2825_CR103","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-016-0360-5","volume":"30","author":"S Perez-Lloret","year":"2016","unstructured":"Perez-Lloret S, Rascol O (2016) Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease. CNS Drugs 30:703\u2013717","journal-title":"CNS Drugs"},{"key":"2825_CR105","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s007020070020","volume":"107","author":"MM Pinter","year":"2000","unstructured":"Pinter MM, Rutgers AW, Hebenstreit E (2000) An openlabel, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson\u2019s disease. J Neural Transm 107:1307\u20131323","journal-title":"J Neural Transm"},{"key":"2825_CR106","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N et al (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513\u2013520","journal-title":"Lancet Neurol"},{"key":"2825_CR107","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","volume":"77","author":"W Poewe","year":"2011","unstructured":"Poewe W, Rascol O, Barone P et al (2011) Extended release pramipexole in early Parkinson disease. Neurology 77:759\u2013766","journal-title":"Neurology"},{"key":"2825_CR108","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/jnnp.72.6.713","volume":"72","author":"O Pogarell","year":"2002","unstructured":"Pogarell O, Gasser T, van Hilten JJ et al (2002) Pramipexole in patients with Parkinson\u2019s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72:713\u2013720","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2825_CR109","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/jnnp.52.4.544","volume":"52","author":"P Pollak","year":"1989","unstructured":"Pollak P, Champay AS, Hommel M et al (1989) Subcutaneous apomorphine in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 52:544","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2825_CR113","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"2825_CR114","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/mds.20988","volume":"21","author":"O Rascol","year":"2006","unstructured":"Rascol O, Brooks DJ, Korczyn AD et al (2006) Development of dyskinesias in a 5-year trial of ropinirole and Ldopa. Mov Disord 21:1844\u20131850","journal-title":"Mov Disord"},{"key":"2825_CR117","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","volume":"10","author":"I Rektorova","year":"2003","unstructured":"Rektorova I, Rektor I, Bares M et al (2003) Pramipexole and pergolide in the treatment of depression in Parkinson\u2019s disease: a national multicentre prospective randomized study. Eur J Neurol 10:399\u2013406","journal-title":"Eur J Neurol"},{"key":"2825_CR119","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/ene.13034","volume":"23","author":"A Rizos","year":"2016","unstructured":"Rizos A, Sauerbier A, Antonini A et al (2016) A European multicentre survey of impulse control behaviours in Parkinson\u2019s disease patients treated with short- and longacting dopamine agonists. Eur J Neurol 23:1255\u20131261","journal-title":"Eur J Neurol"},{"key":"2825_CR121","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AHV Schapira","year":"2011","unstructured":"Schapira AHV, Barone P, Hauser RA et al (2011) Extended-release pramipexole in advanced Parkinson disease. Neurology 77:767\u2013774","journal-title":"Neurology"},{"key":"2825_CR122","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","volume":"12","author":"AH Schapira","year":"2013","unstructured":"Schapira AH, McDermott MP, Barone P et al (2013) Pramipexole in patients with early Parkinson\u2019s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12:747\u2013755","journal-title":"Lancet Neurol"},{"key":"2825_CR123","first-page":"169","volume":"21","author":"AE Schrag","year":"1998","unstructured":"Schrag AE, Brooks DJ, Em B et al (1998) The safety of ropinirole. a selective nonergoline dopamine agonist, in patients with Parkinson\u2019s disease. Clin Neuropharmacol 21:169\u2013175","journal-title":"Clin Neuropharmacol"},{"key":"2825_CR124","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1046\/j.1468-1331.2002.00392.x","volume":"9","author":"A Schrag","year":"2002","unstructured":"Schrag A, Keens J, Warner J (2002) Ropinirole for the treatment of tremor in early Parkinson\u2019s disease. Eur J Neurol 9:253\u2013257","journal-title":"Eur J Neurol"},{"key":"2825_CR126","first-page":"251","volume":"76","author":"RS Schwab","year":"1951","unstructured":"Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson\u2019s disease. Trans Am Neurol Assoc 76:251\u2013253","journal-title":"Trans Am Neurol Assoc"},{"key":"2825_CR127","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1001\/archneur.55.9.1211","volume":"55","author":"KD Sethi","year":"1998","unstructured":"Sethi KD, O\u2019Brien CF, Hammerstad JP et al (1998) Ropinirole for the treatment of early Parkinson\u2019s disease. Arch Neurol 55:1211\u20131216","journal-title":"Arch Neurol"},{"key":"2825_CR130","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/practneurol-2012-000432","volume":"13","author":"G Stern","year":"2013","unstructured":"Stern G (2013) Apolaustic apomorphine. Pract Neurol 13:335\u2013337","journal-title":"Pract Neurol"},{"key":"2825_CR131","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(88)91193-2","volume":"1","author":"CMH Stibe","year":"1988","unstructured":"Stibe CMH, Lees AJ, Kempster PA et al (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1:403\u2013406","journal-title":"Lancet"},{"key":"2825_CR134","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1185\/03007990802387130","volume":"24","author":"F Stocchi","year":"2008","unstructured":"Stocchi F, Hersh BP, Scott BL et al (2008) Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson\u2019s disease: a randomized, doubleblind, non-inferiority crossover study. Curr Med Res Opin 24:2883\u20132895","journal-title":"Curr Med Res Opin"},{"key":"2825_CR135","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/mds.23498","volume":"26","author":"F Stocchi","year":"2011","unstructured":"Stocchi F, Giorgi L, Hunter B, Schapira AH (2011) PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson\u2019s disease. Mov Disord 26:1259\u20131265","journal-title":"Mov Disord"},{"key":"2825_CR136","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1080\/14656566.2016.1219337","volume":"17","author":"F Stocchi","year":"2016","unstructured":"Stocchi F, Torti M, Fossati C (2016) Advances in dopamine receptor agonists for the treatment of Parkinson\u2019s disease. Expert Opin Pharmacother 17:1889\u20131902","journal-title":"Expert Opin Pharmacother"},{"key":"2825_CR138","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1055\/s-0043-110095","volume":"85","author":"L T\u00f6nges","year":"2017","unstructured":"T\u00f6nges L, Ceballos-Baumann A, Honig H et al (2017) Praktische Anwendung der kontinuierlichen Apomorphin- Pumpentherapie. Fortschr Neurol Psychiatr 85:516\u2013535","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2825_CR139","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo- controlled study (RECOVER). Mov Disord 26:90\u201399","journal-title":"Mov Disord"},{"key":"2825_CR140","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1007\/s00415-004-0547-4","volume":"251","author":"HL Tyne","year":"2004","unstructured":"Tyne HL, Parsons J, Sinnott A et al (2004) A 10 year retrospective audit of long-term apomorphine use in Parkinson\u2019s disease. J Neurol 251:1370\u20131374","journal-title":"J Neurol"},{"key":"2825_CR141","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3111\/13696998.2014.979937","volume":"18","author":"E Walter","year":"2015","unstructured":"Walter E, Odin P (2015) Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson\u2019s disease in the UK and Germany. J Med Econ 18:155\u2013165","journal-title":"J Med Econ"},{"key":"2825_CR142","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","volume":"68","author":"RL Watts","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C et al (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272\u2013276","journal-title":"Neurology"},{"key":"2825_CR143","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/mds.22890","volume":"25","author":"R Watts","year":"2010","unstructured":"Watts R, Lyons KE, Pahwa R et al (2010) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson\u2019s disease. Mov Disord 25:858\u2013866","journal-title":"Mov Disord"},{"key":"2825_CR146","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"AL Whone","year":"2003","unstructured":"Whone AL, Watts RL, Stoessel AJ et al (2003) Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurology 54:93\u2013101","journal-title":"Ann Neurology"},{"key":"2825_CR148","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","volume":"67","author":"M Yamamoto","year":"2006","unstructured":"Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease. Neurology 67:1225\u20131229","journal-title":"Neurology"},{"key":"2825_CR150","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s12325-019-00938-1","volume":"36","author":"H Zhao","year":"2019","unstructured":"Zhao H, Ning Y, Cooper J et al (2019) Indirect comparison of ropinirole and pramipexole as levodopa adjunctive therapy in advanced Parkinson\u2019s disease: a systematic review and network meta-analysis. Adv Ther 36:1252\u20131265","journal-title":"Adv Ther"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-024-02825-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T16:03:17Z","timestamp":1732982597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-024-02825-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":102,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2825"],"URL":"https:\/\/doi.org\/10.1007\/s00702-024-02825-8","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WHJ is a consultant and speaker for Abbvie, Bial, Desitin, Esteve, STADA, Zambon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}